SIMILARITIES AND DIFFERENCES IN HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES CONSIDERATIONS FOR DECISION-MAKING: USE OF PATIENT PREFERENCE STUDIES

被引：0
|
作者：
Morrison, S. [1 ]
Kumari, C. [1 ]
Castellano, G. [1 ]
Heinz, S. [2 ]
机构：
[1] Ipsos UK, London, England
[2] Ipsos GmbH, Munich, Bavaria, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA274
引用
收藏
页码：S373 / S373
页数：1
相关论文
共 50 条
  • [1] Use of Patient Preference Studies in HTA Decision Making: A NICE Perspective
    Jacoline C. Bouvy
    Luke Cowie
    Rosemary Lovett
    Deborah Morrison
    Heidi Livingstone
    Nick Crabb
    [J]. The Patient - Patient-Centered Outcomes Research, 2020, 13 : 145 - 149
  • [2] Use of Patient Preference Studies in HTA Decision Making: A NICE Perspective
    Bouvy, Jacoline C.
    Cowie, Luke
    Lovett, Rosemary
    Morrison, Deborah
    Livingstone, Heidi
    Crabb, Nick
    [J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2020, 13 (02): : 145 - 149
  • [3] Interchangeability and substitution of biosimilars: is health technology assessment (HTA) a tool for decision-making?
    Ascef, Bruna de Oliveira
    Leonel da Silva, Renan Goncalves
    de Oliveira Junior, Haliton Alves
    De Soarez, Patricia Coelho
    [J]. CADERNOS DE SAUDE PUBLICA, 2019, 35 (09):
  • [4] Defining the role of the public in Health Technology Assessment (HTA) and HTA-informed decision-making processes
    Street, Jackie
    Stafinski, Tania
    Lopes, Edilene
    Menon, Devidas
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 36 (02) : 87 - 95
  • [5] THE EVOLVING ROLE OF DISEASE-LEVEL PATIENT EXPERIENCE IN HEALTH TECHNOLOGY ASSESSMENT (HTA) AND REGULATORY DECISION-MAKING
    Hudzik, A.
    Sandman, K.
    Pham, S.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S541 - S542
  • [6] DIFFERENCES IN EVIDENCE REQUIREMENTS IN ONCOLOGY DRUG ASSESSMENT BETWEEN HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES AND EMA AND HTA BODIES AMONG THEMSELVES
    Wolters, S.
    Jansen, C.
    Postma, M. J.
    [J]. VALUE IN HEALTH, 2020, 23 : S465 - S466
  • [7] THE ADDED VALUE OF USE OF PATIENT PREFERENCE STUDIES IN POLICY DECISION-MAKING: A LITERATURE REVIEW
    Chachoua, L.
    Germain, N.
    Dabbous, M.
    Francois, C.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S826 - S826
  • [8] DIFFERENCES AND SIMILARITIES IN HTA: A COMPARATIVE ANALYSIS OF THE DECISION-MAKING PROCESSES FOR CANCER DRUGS ACROSS 4 COUNTRIES
    Visintin, E.
    Nicod, E.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A489 - A490
  • [9] PATIENT VOICE AND PATIENT ENGAGEMENT IN VALUE ASSESSMENT FRAMEWORKS AND HTA DECISION-MAKING FOR GENE THERAPIES
    Dabbous, M.
    Raza, J.
    Connelly, B.
    Olid, Gonzalez A.
    Sullivan, N.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S312 - S312
  • [10] COMMON THREADS: REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIESAVTM RECOMMENDATIONS ON REAL-WORLD EVIDENCE (RWE) USE IN DECISION-MAKING
    Jaksa, A.
    Gatto, N.
    Case, A.
    [J]. VALUE IN HEALTH, 2020, 23 : S315 - S316
12345